Search Results - "Favalli, G."

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis by Favalli, Ennio G.

“…Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disorder involving inflammation and progressive destruction of the joints, affecting up to 1%…”
Get full text

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma : results of a randomised trial by MAGGI, R, LISSONI, A, SPINA, F, MELPIGNANO, M, ZOLA, P, FAVALLI, G, COLOMBO, A, FOSSATI, R

“…Patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion >50%, and III) receive adjuvant therapy after surgery but it is not…”
Get full text

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review by Baraliakos, Xenofon, Gensler, Lianne S., D’Angelo, Salvatore, Iannone, Florenzo, Favalli, Ennio G., de Peyrecave, Natasha, Auteri, Simone E., Caporali, Roberto

“…We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score…”
Get full text

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA by Iannone, F., Ferraccioli, G., Sinigaglia, L., Favalli, E. G., Sarzi-Puttini, P., Atzeni, F., Gorla, R., Bazzani, C., Govoni, M., Farina, I., Gremese, E., Carletto, A., Giollo, A., Galeazzi, M., Foti, R., Bianchino, L., La Grasta, L., Lapadula, G.

“…To assess the long-term effectiveness and safety of tocilizumab, abatacept, and tumor necrosis factor-α inhibitors (TNFi), in the Italian real-world setting of…”
Get full text

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry by Manara, Maria, Caporali, Roberto, Favalli, Ennio G, Grosso, Vittorio, Atzeni, Fabiola, Sarzi Puttini, Piercarlo, Gorla, Roberto, Bazzani, Chiara, Fusaro, Enrico, Pellerito, Raffaele, Rocchetta, Pier Andrea, Sinigaglia, Luigi

“…We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre…”
Get full text

Baricitinib for COVID-19: a suitable treatment? by Favalli, Ennio G, Biggioggero, Martina, Maioli, Gabriella, Caporali, Roberto

Get full text

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry by Favalli, Ennio G., Sinigaglia, Luigi, Becciolini, Andrea, Grosso, Vittorio, Gorla, Roberto, Bazzani, Chiara, Atzeni, Fabiola, Sarzi Puttini, Pier C., Fusaro, Enrico, Pellerito, Raffaele, Caporali, Roberto

“…Objectives To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis…”
Get full text

Is there really room for anti-rheumatic drugs in the treatment of COVID-19? by Favalli, EG, Ingegnoli, F, Biggioggero, M, Caporali, R

Get full text

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) by Scarpato, Salvatore, Antivalle, Marco, Favalli, Ennio G., Nacci, Francesca, Frigelli, Sabrina, Bartoli, Francesca, Bazzichi, Laura, Minisola, Giovanni, Matucci Cerinic, Marco

“…Objective. To identify the determinants of anti-TNF-naive patients’ preferences for the route of administration of anti-TNF agents. Methods. The study was…”
Get full text

Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety by Favalli, Ennio G, Caporali, Roberto, Sinigaglia, Luigi, Pipitone, Nicolo', Miniati, Irene, Montecucco, Carlomaurizio, Matucci-Cerinic, Marco

“…Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific…”
Get full text

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study by Creemers, G J, Bolis, G, Gore, M, Scarfone, G, Lacave, A J, Guastalla, J P, Despax, R, Favalli, G, Kreinberg, R, Van Belle, S, Hudson, I, Verweij, J, Ten Bokkel Huinink, W W

“…Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan…”
Get more information

Cancer in women by Pecorelli, S., Favalli, G., Zigliani, L., Odicino, F.

“…Incidence, mortality and survival trends for the most frequent cancers affecting women are presented on a worldwide basis. Data sources are represented by…”
Get full text

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group by Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., Vermorken, J. B.

“…Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate…”
Get full text

Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review by Gossec, Laure, Bessette, Louis, Xavier, Ricardo M, Favalli, Ennio G, Östör, Andrew, Buch, Maya H

“…Treat-to-target (T2T) is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional…”
Get full text

Secukinumab in HLA‐B27 associated uveitis by Miserocchi, Elisabetta, Giuffre, Chiara, Caporali, Roberto, Favalli, Ennio G.

Get full text

Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy by FAVALLI, E. G, MARCHESONI, A, COLOMBO, G. L, SINIGAGLIA, L

“…The aim of this study was to retrospectively examine the pattern of utilization in clinical practice and the costs of therapy of infliximab in the treatment of…”
Get full text

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries by Michelsen, Brigitte, Georgiadis, Stylianos, Di Giuseppe, Daniela, Loft, Anne G., Nissen, Michael J., Iannone, Florenzo, Pombo‐Suarez, Manuel, Mann, Herman, Rotar, Ziga, Eklund, Kari K., Kvien, Tore K., Santos, Maria J., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Wallman, Johan K., Brahe, Cecilie H., Möller, Burkhard, Favalli, Ennio G., Sánchez‐Piedra, Carlos, Nekvindova, Lucie, Tomsic, Matija, Trokovic, Nina, Kristianslund, Eirik K., Santos, Helena, Löve, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Jones, Gareth T., Horst‐Bruinsma, Irene, Ørnbjerg, Lykke M., Østergaard, Mikkel, Hetland, Merete L.

“…Objective There is a lack of real‐life studies on interleukin‐17 (IL‐17) inhibition in psoriatic arthritis (PsA). We assessed real‐life 6‐ and 12‐month…”
Get full text

Biomarkers in psoriatic arthritis: a systematic literature review by Generali, Elena, Scirè, Carlo A, Favalli, Ennio G, Selmi, Carlo

“…Psoriatic arthritis (PsA) is characterized by chronic inflammation of peripheral joints and axial skeleton, associated with a strong genetic background…”
Get more information

Quality of life: Gynaecological cancers by Pignata, S., Ballatori, E., Favalli, G., Scambia, G.

“…The clinical management of gynaecological cancer patients has been mainly focused on prolonging the survival of the patients. Thus, research on MEDLINE using…”
Get full text

Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA by Iannone, Florenzo, Favalli, Ennio G., Caporali, Roberto, D’Angelo, Salvatore, Cantatore, Francesco Paolo, Sarzi-Puttini, Piercarlo, Foti, Rosario, Conti, Fabrizio, Carletto, Antonio, Gremese, Elisa, Cauli, Alberto, Ramonda, Roberta, Palermo, Adalgisa, Epis, Oscar, Priora, Marta, Bergossi, Francesca, Frediani, Bruno, Salaffi, Fausto, Lopalco, Giuseppe, Cacciapaglia, Fabio, Marchesoni, Antonio, Biggioggiero, Martina, Bugatti, Serena, Balduzzi, Silvia, Carriero, Antonio, Corrado, Addolorata, Bongiovanni, Sara, Benenati, Alessia, Miranda, Francesca, Fracassi, Elena, Perra, Daniela, Ferraccioli, Gianfranco, Lapadula, Giovanni

“…•In a large cohort of patients with SpA and PsA from the real life, golimumab has shown to be as effective in 1-biologic IR as in biologic-naive patients, with…”
Get full text